50,000 Shares in Bioventus Inc. (NYSE:BVS) Bought by Caption Management LLC

Caption Management LLC purchased a new position in Bioventus Inc. (NYSE:BVS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 50,000 shares of the company's stock, valued at approximately $525,000. Caption Management LLC owned approximately 0.06% of Bioventus at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Balyasny Asset Management L.P. acquired a new position in shares of Bioventus in the fourth quarter worth about $133,000. Bank of America Corp DE boosted its stake in Bioventus by 3.6% in the 4th quarter. Bank of America Corp DE now owns 174,554 shares of the company's stock worth $1,833,000 after purchasing an additional 6,113 shares during the period. BNP Paribas Financial Markets purchased a new position in Bioventus during the 4th quarter worth approximately $1,659,000. Algert Global LLC acquired a new stake in Bioventus during the 4th quarter valued at $704,000. Finally, Northern Trust Corp lifted its holdings in shares of Bioventus by 7.3% in the fourth quarter. Northern Trust Corp now owns 345,916 shares of the company's stock valued at $3,632,000 after purchasing an additional 23,523 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company's stock.

Bioventus Stock Down 1.5 %

Shares of Bioventus stock traded down $0.10 on Friday, hitting $6.70. 501,735 shares of the company traded hands, compared to its average volume of 452,902. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12-month low of $5.25 and a 12-month high of $14.38. The company has a 50-day moving average price of $8.40 and a 200 day moving average price of $10.10. The company has a market cap of $549.02 million, a PE ratio of -10.98 and a beta of 0.95.

Insider Buying and Selling at Bioventus

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the stock in a transaction on Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $29,333.75. Following the transaction, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.16. This represents a 2.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares of the company's stock, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,208 shares of company stock worth $226,138 over the last 90 days. 32.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BVS has been the topic of a number of research analyst reports. Craig Hallum set a $15.00 price target on Bioventus and gave the company a "buy" rating in a report on Wednesday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.